Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 320 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HSV Clear all
Completed Phase 3 Interventional Accepts healthy volunteers Results available

HerpeVac Trial for Young Women

NCT00057330
View directory record Official record
Conditions
Herpes Simplex Infection
Interventions
HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine, Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 30 Years · Female only
Enrollment
8,323 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
67
States / cities
Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Phase 2 Interventional

Efficacy, Tolerability, and Safety of NXN-462 in Patients With Post-Herpetic Neuralgia

NCT01748877
View directory record Official record
Conditions
Post Herpetic Neuralgia
Interventions
NXN-462, Placebo
Drug
Lead sponsor
NeurAxon Inc.
Industry
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
22
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2014 · Synced Oct 31, 2026, 5:17 PM EDT
Completed No phase listed Observational

Development of Serologic Assays for Human Herpes Virus-8

NCT00395278
View directory record Official record
Conditions
Kaposi Sarcoma, HIV Infection
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
394 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 31, 2026, 5:17 PM EDT
Recruiting Phase 2 Interventional

Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)

NCT07308886
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
CYT107
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2037
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Phase 1 Interventional

Trial Evaluating Safety, Tolerability and Immune Response of AG-707

NCT00231049
View directory record Official record
Conditions
Genital Herpes
Interventions
AG-707
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
Indianapolis, Indiana • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 27, 2008 · Synced Oct 31, 2026, 5:17 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Tolerability of a Recombinant Herpes Zoster Vaccine

NCT05750017
View directory record Official record
Conditions
Herpes Zoster, Vaccine-Preventable Diseases
Interventions
Low Dose Recombinant Herpes Zoster Vaccine (LZ901), High Dose Recombinant Herpes Zoster Vaccine (LZ901), Placebo
Biological · Drug
Lead sponsor
Beijing Luzhu Biotechnology Co., Ltd.
Other
Eligibility
50 Years to 70 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Systems Biology of Zoster Vaccine

NCT04047979
View directory record Official record
Conditions
Zoster, Zoster Varicella, Shingles, Chicken Pox
Interventions
Shingrix®
Biological
Lead sponsor
Emory University
Other
Eligibility
50 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating Three Grams Daily Valacyclovir in Patients With Chronic Hepatitis C and HSV-2 Infection (Phase I)

NCT01453075
View directory record Official record
Conditions
Chronic Hepatitis C Infection
Interventions
Valacyclovir, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Not applicable Interventional

Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS

NCT00002181
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Cidofovir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
15
States / cities
Long Beach, California • Los Angeles, California • Oceanside, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Phase 4 Interventional Results available

VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2

NCT00306293
View directory record Official record
Conditions
Herpes Labialis
Interventions
valacyclovir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
18
States / cities
Anaheim, California • Carmichael, California • Fair Oaks, California + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 31, 2026, 5:17 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Viral Infections in Healthy and Immunocompromised Hosts

NCT01306084
View directory record Official record
Conditions
Anogenital Herpes, COVID-19, Herpes Labialis
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 120 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine

NCT05871541
View directory record Official record
Conditions
Herpes Zoster (HZ), Shingles, Infectious Disease
Interventions
JCXH-105, Active Control (Shingrix)
Biological
Lead sponsor
Immorna Biotherapeutics, Inc.
Industry
Eligibility
50 Years to 69 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Hollywood, Florida • Tampa, Florida • Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents

NCT04523246
View directory record Official record
Conditions
Herpes Zoster, Allergy and Immunology, Corona Virus Infection
Interventions
SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline
Biological · Drug
Lead sponsor
University of Oklahoma
Other
Eligibility
65 Years to 100 Years
Enrollment
217 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 22, 2023 · Synced Oct 31, 2026, 5:17 PM EDT
Recruiting Phase 2 Interventional

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

NCT03541928
View directory record Official record
Conditions
High-risk Prostate Cancer, Prostate Cancer
Interventions
HSV-Tk, Valacyclovir, Bicalutamide, Leuprolide Acetate, Brachytherapy, External beam radiotherapy, Radical prostatectomy
Drug · Radiation · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Early Phase 1 Interventional Results available

Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors

NCT03771157
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia (WM)
Interventions
Shingrix vaccine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 31, 2026, 5:17 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia

NCT00914628
View directory record Official record
Conditions
Acute Leukemia (Category)
Interventions
HSV-Tk, T-cell depleted or T-cell replete strategies
Genetic · Other
Lead sponsor
AGC Biologics S.p.A.
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
3
States / cities
Chicago, Illinois • St Louis, Missouri • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 31, 2026, 5:17 PM EDT
Recruiting No phase listed Observational

The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise

NCT01011712
View directory record Official record
Conditions
EBV, HSV, VZV, HPV, CMV
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 100 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis

NCT00361881
View directory record Official record
Conditions
Herpes Labialis
Interventions
ME-609, acyclovir in ME-609 vehicle, Vehicle
Drug
Lead sponsor
Medivir
Industry
Eligibility
18 Years and older
Enrollment
1,443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Aug 18, 2008 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Phase 2 Interventional

Comparison of Brovavir Versus Acyclovir in the Treatment of Herpes in HIV-Infected Patients

NCT00000953
View directory record Official record
Conditions
HIV Infections, Chickenpox
Interventions
Sorivudine, Acyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Birmingham, Alabama • Los Angeles, California • Martinez, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2011 · Synced Oct 31, 2026, 5:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster

NCT03553472
View directory record Official record
Conditions
Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
35 Years to 49 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 19, 2019 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Phase 1 Interventional Results available

Neonatal Phase 1 Valacyclovir Study

NCT05468619
View directory record Official record
Conditions
Herpes Simplex
Interventions
Valacyclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 2 Days
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
12
States / cities
Birmingham, Alabama • Atlanta, Georgia • Louisville, Kentucky + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Oct 31, 2026, 5:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM

NCT03603405
View directory record Official record
Conditions
Glioblastoma, Anaplastic Astrocytoma
Interventions
ADV/HSV-tk (gene therapy)
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 31, 2026, 5:17 PM EDT
Recruiting Phase 1Phase 2 Interventional

HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM

NCT03596086
View directory record Official record
Conditions
Glioblastoma Multiforme, Astrocytoma, Grade III
Interventions
ADV/HSV-tk (gene therapy)
Drug
Lead sponsor
David Baskin MD
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 31, 2026, 5:17 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Long-term Follow-up Study (ZOE-LTFU) of Two Studies 110390 (ZOSTER-006) and 113077 (ZOSTER-022) to Assess the Efficacy, Safety, and Immunogenicity Persistence of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine and Assessment of 1 or 2 Additional Doses in Two Subgroups of Older Adults

NCT02723773
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster Vaccine GSK1437173A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
7,539 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2024
U.S. locations
25
States / cities
Phoenix, Arizona • Spring Valley, California • Hallandale, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2025 · Synced Oct 31, 2026, 5:17 PM EDT